Sera Prognostics, Inc. (SERA) Earnings Call Transcripts

Sera Prognostics, Inc.'s Latest Earnings Call - Q1 FY2026

In the first quarter of fiscal year 2026, Sera Prognostics reported revenue of $14,000, a decline from $38,000 in the same quarter last year, reflecting ongoing challenges in their commercialization strategy. The net loss for the quarter was $8.4 million, slightly higher than the $8.2 million loss reported a year ago. Management signaled a cautious outlook for revenue in 2026, indicating that it could remain modest and uneven as they continue to push for reimbursement and awareness, while also expecting to reduce operating expenses by nearly $10 million annually starting in 2027.

Reported metrics

Guidance from management

Management expects revenue in 2026 to remain modest and uneven, with increasing pull-through anticipated later in the year and into 2027. They also expect to reduce operating expenses by nearly $10 million annually starting in 2027.

What management said

I got you. That's not unreasonable. As you know, we don't report the volume of orders, but it's certainly not an unreasonable number to be thinking about. And given your question, Dan, and our conversations, of course, we'll -- as soon as we see steadiness, we'll start reporting on it. But yes, that assumption is not unreasonable.

Thank you so much, operator. In summary, we're building the medical reimbursement and advocacy foundations necessary for commercialization and guideline inclusion efforts, and the engagement we're seeing across stakeholders reinforces our confidence in the opportunity ahead. Thank you so much, everyone, for your time today, and we look forward to continuing to share our progress steadily each quarter.

What analysts pressed on

Analysts expressed concerns regarding the slow pace of revenue growth and the impact of ongoing operational shifts on future performance. There were questions about the timeline for achieving positive coverage decisions from Medicaid programs and the effectiveness of new sales representatives in driving adoption.

Main topics on the call

• Revenue Decline — Sera Prognostics reported revenue of $14,000 for Q1 2026, down from $38,000 in Q1 2025. Management noted that this decline reflects the 'timing and nature of our geographically targeted commercialization strategy.'
• Cost Management Initiatives — Operating expenses increased slightly to $9.4 million from $9.3 million year-over-year. However, management expects to reduce operating expenses by nearly $10 million annually starting in 2027, which they believe will en...
• Commercialization Strategy — Management emphasized their shift towards a more direct commercial effort, stating, 'we are prioritizing investments in payer engagement, market access and clinical adoption.' This strategic pivot aims to extend their ca...
• Partnership Expansion — Sera launched its third partnership program in Q1 2026, which is expected to reach over 350 providers across three states. Management indicated that they are engaged with 13 payers across 15 states, reflecting a growing ...

Read the full Sera Prognostics, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 19 Sera Prognostics, Inc. earnings call transcripts on record, spanning November 9, 2022 to August 12, 2026. Based on this history, Sera Prognostics, Inc. reports quarterly. The most recent call on file is dated August 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

SERA

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

19

First call

November 9, 2022

Most recent

August 12, 2026

Reporting cadence

quarterly